Journal of Reconstructive Urology

.: REVIEW
Alternative Pharmacological Approach to Male Infertility: Anti-Aromatase Compounds: A Systematic Review
Erkek İnfertilitesine Alternatif Farmakolojik Yaklaşım: Anti-Aromataz Bileşikler: Sistematik Derleme
Münevver Nazlıcan ZENGİNa , Yasemin ŞAHİNa , Osman ÇİFTÇİa
aDepartment of Pharmacology, Pamukkale University Faculty of Medicine, Denizli, Türkiye
J Reconstr Urol. 2023;13(1):28-37
doi: 10.5336/urology.2022-92478
Article Language: EN
Full Text
ABSTRACT
 Infertility is a reproductive system disease in which pregnancy does not occur despite long-term, regular and unprotected sexual intercourse. In the near future, it is estimated that approximately 15% of the world population will be affected by infertility and the majority of this will be male-induced infertility. In male infertility, 90% defective sperm production is effective and it is known that in infertile men, as a result of the increase in estrogen levels due to aromatase activity, the testosterone/estradiol ratio may decrease and spermatogenesis is impaired. Therefore, research on increasing intratesticular testosterone levels and improving impaired spermatogenesis has focused on aromatase inhibitors. However, since the efficacy and safety of aromatase inhibitors have not been clarified, it has been thought that anti-aromatase compounds with fewer side effects and stronger efficacy can be used as alternative therapeutic agents in the treatment of infertility. Phytoestrogens are estrogenic plant-derived compounds. Many have been shown to have aromatase inhibition, thereby increasing testosterone levels. In addition, it is known that there are different mechanisms that affect spermatogenesis apart from binding to estrogen receptors in their effects on the male reproductive system. Therefore, our aim is to review the latest developments and treatment approaches to natural polyphenolic compounds with anti-aromatase activity in male infertility. According to the literature, the most commonly used anti-aromatase compounds include resveratrol, quercetin, apigenin, and naringenin. All the compounds in this review were found to have positive effects on male infertility.

Keywords: Aromatase inhibitors; infertility, male; estrogens; spermatogenesis; drug therapy
ÖZET
 İnfertilite; uzun süreli, düzenli ve korunmasız cinsel ilişkiye rağmen gebeliğin oluşmadığı bir reprodüktif sistem hastalığıdır. Yakın gelecekte ise dünya nüfusunun yaklaşık %15'inin infertiliteden etkileneceği ve bunun çoğunluğunun erkek kaynaklı infertilite olacağı tahmin edilmektedir. Erkek infertilitesinde %90 oranında kusurlu sperm üretimi etkilidir ve infertil erkeklerde, aromataz aktivitesine bağlı östrojen seviyelerindeki artış sonucunda testosteron/östradiol oranının azalabildiği ve spermatogenezin bozulduğu bilinmektedir. Bu nedenle intratestiküler testosteron seviyelerinin artırılması ve bozulmuş spermatogenezin iyileştirilmesine yönelik araştırmalarda aromataz inhibitörleri üzerine odaklanılmıştır. Ancak aromataz inhibitörlerinin etkinliği ve güvenirliliği netlik kazanmadığı için infertilite tedavisinde daha az yan etki ve daha güçlü etkinliğe sahip anti-aromataz bileşikleri alternatif terapötik ajanlar olarak kullanılabileceği düşünülmüştür. Fitoöstrojenler, östrojenik bitkisel kaynaklı bileşiklerdir. Birçoğunun aromataz inhibisyonuna sahip olduğu ve bu şekilde testosteron düzeyini artırdığı gösterilmiştir. Bunun yanında, erkek üreme sistemi üzerindeki etkilerinde östrojen reseptörlerine bağlanmanın dışında spermatogenezi etkileyen farklı mekanizmaların olduğu da bilinmektedir. Bu yüzden amacımız, erkek infertilitesinde anti-aromataz etkinliğe sahip doğal polifenolik bileşikler hakkında son gelişmeleri ve tedavi yaklaşımlarını derlemektir. Literatüre göre en yaygın kullanılan anti-aromataz bileşikler arasında resveratrol, kuersetin, apigenin ve naringenin yer almaktadır. Bu derlemede yer alan tüm bileşiklerin ise erkek infertilitesinde olumlu etkiler gösterdiği belirlenmiştir.

Anahtar Kelimeler: Aromataz inhibitörleri; infertilite, erkek; östrojenler; spermatogenez; ilaç tedavisi
REFERENCES:
  1. Li WN, Jia MM, Peng YQ, Ding R, Fan LQ, Liu G. Semen quality pattern and age threshold: a retrospective cross-sectional study of 71,623 infertile men in China, between 2011 and 2017. Reprod Biol Endocrinol. 2019;17(1):107. [Crossref]  [PubMed]  [PMC] 
  2. Liu Y, Ding Z. Obesity, a serious etiologic factor for male subfertility in modern society. Reproduction. 2017;154(4):R123-31. [Crossref]  [PubMed] 
  3. de Ronde W, de Jong FH. Aromatase inhibitors in men: effects and therapeutic options. Reprod Biol Endocrinol. 2011;9:93. [Crossref]  [PubMed]  [PMC] 
  4. Aromatase Inhibitors. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Published online July 27, 2017. [Cited: June 14, 2022]. Available from: [Link] 
  5. Xu X, Sun M, Ye J, Luo D, Su X, Zheng D, et al. The effect of aromatase on the reproductive function of obese males. Horm Metab Res. 2017;49(8):572-9. [Crossref]  [PubMed] 
  6. Kaymak E, Yıldırım AB. Aromatase, estrogen and male reproduction: a review. Experimental and Applied Medical Science. 2020;1(3):100-8. [Crossref] 
  7. Hess R, Cooke PS. Estrogen in the male: a historical perspective. Biology of Reproduction. 2018;99(1):27-44. [Crossref]  [PubMed]  [PMC] 
  8. Carreau S, Wolczynski S, Galeraud-Denis I. Aromatase, oestrogens and human male reproduction. Philos Trans R Soc Lond B Biol Sci. 2010;365(1546):1571-9. [Crossref]  [PubMed]  [PMC] 
  9. Carreau S, Lambard S, Delalande C, Denis-Galeraud I, Bilinska B, Bourguiba S. Aromatase expression and role of estrogens in male gonad: a review. Reprod Biol Endocrinol. 2003;1:35. [Crossref]  [PubMed]  [PMC] 
  10. Allan C, Couse J, Simanainen U, Spaliviero J, Jimenez M, Rodriquez K, et al. Estradiol induction of spermatogenesis is mediated via an estrogen receptor-α mechanism involving neuroendocrine activation of follicle-stimulating hormone. [Cite: June 14, 2022]. Endocrinology. 2010;151(6):2800-10. [Crossref]  [PubMed]  [PMC] 
  11. Raven G, de Jong FH, Kaufman JM, de Ronde W. In men, peripheral estradiol levels directly reflect the action of estrogens at the hypothalamo-pituitary level to inhibit gonadotropin secretion. J Clin Endocrinol Metab. 2006;91(9):3324-8. [Crossref]  [PubMed] 
  12. Muller M, van den Beld AW, van der Schouw YT, Grobbee DE, Lamberts SW. Effects of dehydroepiandrosterone and atamestane supplementation on frailty in elderly men. J Clin Endocrinol Metab. 2006;91(10):3988-91. [Crossref]  [PubMed] 
  13. Izawa H, Kohara M, Aizawa K, Suganuma H, Inakuma T, Watanabe G, et al. Alleviative effects of quercetin and onion on male reproductive toxicity induced by diesel exhaust particles. Biosci Biotechnol Biochem. 2008;72(5):1235-41. [Crossref]  [PubMed] 
  14. Farombi EO, Adedara IA, Akinrinde SA, Ojo OO, Eboh AS. Protective effects of kolaviron and quercetin on cadmium-induced testicular damage and endocrine pathology in rats. Andrologia. 2012;44(4):273-84. [Crossref]  [PubMed] 
  15. Guvvala P, Ravindra J, Rajani C, Sivaram M, Selvaraju S. Protective role of epigallocatechin-3-gallate on arsenic induced testicular toxicity in Swiss albino mice. [Cited: July 4, 2022]. Biomedicine & Pharmacotherapy. 2017;96:685-94. [Crossref]  [PubMed] 
  16. Peters A, Tadi P. Aromatase Inhibitors. 2022 Jul 5. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. [PubMed] 
  17. Schlegel PN. Aromatase inhibitors for male infertility. Fertil Steril. 2012;98(6):1359-62. [Crossref]  [PubMed] 
  18. Yang C, Li P, Li Z. Clinical application of aromatase inhibitors to treat male infertility. Hum Reprod Update. 2021;28(1):30-50. [Crossref]  [PubMed] 
  19. Desmawati D, Sulastri D. Phytoestrogens and their health effect. Open Access Maced J Med Sci. 2019;7(3):495-9. [Crossref]  [PubMed]  [PMC] 
  20. Gorzkiewicz J, Bartosz G, Sadowska-Bartosz I. The potential effects of phytoestrogens: the role in neuroprotection. Molecules. 2021;26(10):2954. [Crossref]  [PubMed]  [PMC] 
  21. Giwercman A. Estrogens and phytoestrogens in male infertility. Curr Opin Urol. 2011;21(6):519-26. [Crossref]  [PubMed] 
  22. Povey AC, Clyma JA, McNamee R, Moore HD, Baillie H, Pacey AA, et al; Participating Centres of Chaps-UK. Phytoestrogen intake and other dietary risk factors for low motile sperm count and poor sperm morphology. Andrology. 2020;8(6):1805-14. [Crossref]  [PubMed] 
  23. Türkmen NB. Pembrolizumab verilen sıçanlarda olası testis toksisitesine karşı aromataz inhibitörlerinin etkisi. [Doktora tezi]. Erişim tarihi: 15.08.2022. Erişim linki: [Link] 
  24. Singh AP, Singh R, Verma SS, Rai V, Kaschula CH, Maiti P, et al. Health benefits of resveratrol: Evidence from clinical studies. Med Res Rev. 2019;39(5):1851-91. [Crossref]  [PubMed] 
  25. Shabani Nashtaei M, Amidi F, Sedighi Gilani MA, Aleyasin A, Bakhshalizadeh S, Naji M, et al. Protective features of resveratrol on human spermatozoa cryopreservation may be mediated through 5' AMP-activated protein kinase activation. Andrology. 2017;5(2):313-26. [Crossref]  [PubMed] 
  26. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012;15(5):675-90. [Crossref]  [PubMed]  [PMC] 
  27. Cui N, Xu Z, Zhao X, Yuan M, Pan L, Lu T, et al. In vivo effect of resveratrol-cellulose aerogel drug delivery system to relieve inflammation on sports osteoarthritis. Gels. 2022;8(9):544. [Crossref]  [PubMed]  [PMC] 
  28. Guo S, Zhou Y, Xie X. Resveratrol inhibiting TGF/ERK signaling pathway can improve atherosclerosis: backgrounds, mechanisms and effects. Biomed Pharmacother. 2022;155:113775. [Crossref]  [PubMed] 
  29. Díaz-Ruiz R, Laca A, Sánchez M, Fernández MR, Matos M, Gutiérrez G. Addition of trans-resveratrol-loaded highly concentrated double emulsion to yoghurts: effect on physicochemical properties. Int J Mol Sci. 2021;23(1):85. [Crossref]  [PubMed]  [PMC] 
  30. Chen Z, Farag MA, Zhong Z, Zhang C, Yang Y, Wang S, et al. Multifaceted role of phyto-derived polyphenols in nanodrug delivery systems. Adv Drug Deliv Rev. 2021;176:113870. [Crossref]  [PubMed] 
  31. Ciftci O, Ozdemir I, Aydin M, Beytur A. Beneficial effects of chrysin on the reproductive system of adult male rats. Andrologia. 2012;44(3):181-6. [Crossref]  [PubMed] 
  32. Del Fabbro L, Jesse CR, de Gomes MG, Borges Filho C, Donato F, Souza LC, et al. The flavonoid chrysin protects against zearalenone induced reproductive toxicity in male mice. Toxicon. 2019;165:13-21. [Crossref]  [PubMed] 
  33. El-Sisi AE, El-Sayad ME, Abdelsalam NM. Protective effects of mirtazapine and chrysin on experimentally induced testicular damage in rats. Biomed Pharmacother. 2017;95:1059-66. [Crossref]  [PubMed] 
  34. Parlak Ak T, Tatli Seven P, Gur S, Gul B, Yaman M, Seven I. Chrysin and flunixin meglumine mitigate overloaded copper-induced testicular and spermatological damages via modulation of oxidative stress and apoptosis in rats. Andrologia. 2022;54(2):e14327. [Crossref]  [PubMed] 
  35. Adangale SC, Wairkar S. Potential therapeutic activities and novel delivery systems of chrysin-a nature's boon. Food Biosci. 2022;45:101316. [Crossref] 
  36. Imran M, Aslam Gondal T, Atif M, Shahbaz M, Batool Qaisarani T, Hanif Mughal M, et al. Apigenin as an anticancer agent. Phytother Res. 2020;34(8):1812-28. [Crossref]  [PubMed] 
  37. Yan X, Qi M, Li P, Zhan Y, Shao H. Apigenin in cancer therapy: anti-cancer effects and mechanisms of action. Cell Biosci. 2017;7:50. [Crossref]  [PubMed]  [PMC] 
  38. Madunić J, Madunić IV, Gajski G, Popić J, Garaj-Vrhovac V. Apigenin: a dietary flavonoid with diverse anticancer properties. Cancer Lett. 2018;413:11-22. [Crossref]  [PubMed] 
  39. Wang B, Zhang M, Guo J, Liu Z, Zhou R, Guo F, et al. The effects of flavonoid apigenin on male reproductive health: ınhibition of spermatogonial proliferation through downregulation of Prmt7/Akt3 pathway. Int J Mol Sci. 2021;22(22):12209. [Crossref]  [PubMed]  [PMC] 
  40. Apigenin and Baicalin, Each Alone or in Low Dose Combination, Attenuated Chloroquine Induced Male Infertility in Adult Rats | Akilah | Thai Journal of Pharmaceutical Sciences (TJPS). [Cited: July 4, 2022]. Available from: [Link] 
  41. Ye RJ, Yang JM, Hai DM, Liu N, Ma L, Lan XB, et al. Interplay between male reproductive system dysfunction and the therapeutic effect of flavonoids. Fitoterapia. 2020;147:104756. [Crossref]  [PubMed] 
  42. Li W, Pandey A, Yin X, Chen J, Stocco DM, Grammas P, et al. Effects of apigenin on steroidogenesis and steroidogenic acute regulatory gene expression in mouse Leydig cells. [Cited: July 4, 2022]. The Journal of Nutritional Biochemistry. 2011;22(3):212-8. [Crossref]  [PubMed]  [PMC] 
  43. Zhou Y, Yu Y, Lv H, Zhang H, Liang T, Zhou G, et al. Apigenin in cancer therapy: From mechanism of action to nano-therapeutic agent. Food Chem Toxicol. 2022;168:113385. [Crossref]  [PubMed] 
  44. Patel K, Singh GK, Patel DK. A review on pharmacological and analytical aspects of naringenin. Chin J Integr Med. 2018;24(7):551-60. [Crossref]  [PubMed] 
  45. Dikshit P, Tyagi MK, Shukla K, Gambhir JK, Shukla R. Antihypercholesterolemic and antioxidant effect of sterol rich methanol extract of stem of Musa sapientum (banana) in cholesterol fed wistar rats. J Food Sci Technol. 2016;53(3):1690-7. [Crossref]  [PubMed]  [PMC] 
  46. Braca A, Sortino C, Politi M, Morelli I, Mendez J. Antioxidant activity of flavonoids from Licania licaniaeflora. [Cited: July 4, 2022]. Journal of Ethnopharmacology. 2002;79(3):379-81. [Crossref]  [PubMed] 
  47. Singh AK, Raj V, Keshari AK, Rai A, Kumar P, Rawat A, et al. Isolated mangiferin and naringenin exert antidiabetic effect via PPARγ/GLUT4 dual agonistic action with strong metabolic regulation. Chem Biol Interact. 2018;280:33-44. [Crossref]  [PubMed] 
  48. Badary O, Abdel-Maksoud S, Ahmed WA, Owieda GH. Naringenin attenuates cisplatin nephrotoxicity in rats. [Cited: July 4, 2022]. Life Sciences. 2005;76(18):2125-35. [Crossref]  [PubMed] 
  49. Chen D, Chen MS, Cui QC, Yang H, Dou QP. Structure-proteasome-inhibitory activity relationships of dietary flavonoids in human cancer cells. Front Biosci. 2007;12:1935-45. [Crossref]  [PubMed] 
  50. El-Kersh DM, Ezzat SM, Salama MM, Mahrous EA, Attia YM, Ahmed MS, et al. Anti-estrogenic and anti-aromatase activities of citrus peels major compounds in breast cancer. Sci Rep. 2021;11(1):7121. [Crossref]  [PubMed]  [PMC] 
  51. Ibrahim AR, Abul-Hajj YJ. Aromatase inhibition by flavonoids. J Steroid Biochem Mol Biol. 1990;37(2):257-60. [Crossref]  [PubMed] 
  52. Al-Oanzi ZH. Erectile dysfunction attenuation by naringenin in streptozotocin-induced diabetic rats. J Food Biochem. 2019;43(7):e12885. [Crossref]  [PubMed] 
  53. Torrisi C, Guardia M di, Castelli F, Sarpietro MG. Naringenin release to biomembrane models by incorporation into nanoparticles. Experimental evidence using differential scanning calorimetry. Surfaces 2021;4(4):295-305. [Crossref] 
  54. Adana MY, Akang EN, Peter AI, Jegede AI, Naidu ECS, Tiloke C, et al. Naringenin attenuates highly active antiretroviral therapy-induced sperm DNA fragmentations and testicular toxicity in Sprague-Dawley rats. Andrology. 2018;6(1):166-75. [Crossref]  [PubMed] 
  55. Michala AS, Pritsa A. Quercetin: a molecule of great biochemical and clinical value and its beneficial effect on diabetes and cancer. Diseases. 2022;10(3):37. [Crossref]  [PubMed]  [PMC] 
  56. Aherne S, O'Brien NM. Mechanism of protection by the flavonoids, quercetin and rutin, against tert-butylhydroperoxide-and menadione-induced DNA single strand breaks in Caco-2. [Cited: July 5, 2022]. Free Radical Biology and Medicine. 2000;29(6):507-14. [Crossref]  [PubMed] 
  57. Khaki A, Fathiazad F, Nouri M, Khaki A, Maleki NA, Khamnei HJ, et al. Beneficial effects of quercetin on sperm parameters in streptozotocin-induced diabetic male rats. Phytother Res. 2010;24(9):1285-91. [Crossref]  [PubMed] 
  58. Silva E, Cajueiro J, Silva S, Soares PC, Gueraa MMP. Effect of antioxidants resveratrol and quercetin on in vitro evaluation of frozen ram sperm. [Cited: July 5, 2022]. Theriogenology. 2012;77(8):1722-6. [Crossref]  [PubMed] 
  59. Taepongsorat L, Tangpraprutgul P, Kitana N, Malaivijitnond S. Stimulating effects of quercetin on sperm quality and reproductive organs in adult male rats. Asian J Androl. 2008;10(2):249-58. [Crossref]  [PubMed] 
  60. Ranawat P, Kaushik G, Saikia UN, Pathak CM, Khanduja KL. Quercetin impairs the reproductive potential of male mice. Andrologia. 2013;45(1):56-65. [Crossref]  [PubMed] 
  61. Nam JS, Sharma AR, Nguyen LT, Chakraborty C, Sharma G, Lee SS. Application of bioactive quercetin in oncotherapy: from nutrition to nanomedicine. Molecules. 2016;21(1):E108. [Crossref]  [PubMed]  [PMC] 
  62. Cui X, Jing X, Wu X, Yan M. Protective effect of resveratrol on spermatozoa function in male infertility induced by excess weight and obesity. Mol Med Rep. 2016;14(5):4659-65. [Crossref]  [PubMed]  [PMC] 
  63. Illiano E, Trama F, Zucchi A, Iannitti RG, Fioretti B, Costantini E. Resveratrol-based multivitamin supplement increases sperm concentration and motility in idiopathic male infertility: a pilot clinical study. J Clin Med. 2020;9(12):4017. [Crossref]  [PubMed]  [PMC] 
  64. Golmohammadi MG, Khoshdel F, Salimnejad R. Protective effect of resveratrol against bisphenol A-induced reproductive toxicity in male mice. Toxin Rev. 2021. [Crossref] 
  65. Fabbro L del, Jesse CR, Gomes de Gomes M, Filho CB, Donato F, Spuza LC, et al. The flavonoid chrysin protects against zearalenone induced reproductive toxicity in male mice. [Cited: July 4, 2022]. Toxicon. 2019;165:13-21. [Crossref]  [PubMed] 
  66. Ileriturk M, Benzer F, Aksu EH, Yildirim S, Kandemir FM, Dogan T, et al. Chrysin protects against testicular toxicity caused by lead acetate in rats with its antioxidant, anti-inflammatory, and antiapoptotic properties. J Food Biochem. 2021;45(2):e13593. [Crossref]  [PubMed] 
  67. Dang Y, Li Z, Wei Q, Zhang R, Xue H, Zhang Y. Protective effect of apigenin on acrylonitrile-induced inflammation and apoptosis in testicular cells via the NF-κB pathway in rats. Inflammation. 2018;41(4):1448-59. [Crossref]  [PubMed] 
  68. Kopalli SR, Yoo SK, Kim B, Kim SK, Koppula S. Apigenin isolated from Carduus crispus protects against H2O2-induced oxidative damage and spermatogenic expression changes in GC-2spd sperm cells. Molecules. 2022;27(6):1777. [Crossref]  [PubMed]  [PMC] 
  69. Taşlıdere A, Türkmen NB, Ciftci O, Aydın M. Investigation into the protective effects of Naringenin in phthalates-induced reproductive damage. Eur Rev Med Pharmacol Sci. 2022;26(10):3419-29. [PubMed] 
  70. Moretti E, Mazzi L, Terzuoli G, Bonechi C, Iacoponi F, Martini S, et al. Effect of quercetin, rutin, naringenin and epicatechin on lipid peroxidation induced in human sperm. Reprod Toxicol. 2012;34(4):651-7. [Crossref]  [PubMed] 
  71. Diao R, Gan H, Tian F, Cai X, Zhen W, Song X, et al. In vitro antioxidation effect of Quercetin on sperm function from the infertile patients with leukocytospermia. Am J Reprod Immunol. 2019;82(3):e13155. [Crossref]  [PubMed] 
  72. Zribi N, Chakroun N, Abdallah F, Elleuch H, Sellami A, Gargouri J, et al. Effect of freezing-thawing process and quercetin on human sperm survival and DNA integrity. [Cited: July 5, 2022]. Cryobiology. 2012;65(3):326-31. [Crossref]  [PubMed] 
  73. Karabulut S, Korkmaz O, Altun CE, Zergeroğlu AD, Keskin İ. Quercetin enhances human sperm motility in a dose and time dependent manner. Acta Pharmaceutica Sciencia. 2020;58(2). [Crossref] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com